Analysis Note

ControlBrain

Application

Research Sub CategoryNeurodegenerative Diseases

Detect BACE using this Anti-BACE Antibody, C-terminus, clone 61-3E7 validated for use in IP & WB.

Research CategoryNeuroscience

Western blotting: 1 µg/mL; recognizes pro and mature forms: ~60-75kDa on reducing westerns. BACE is N-terminally glycosylated which causes the wide size range.

Immunohistochemistry on paraformaldehyde fixed tissues from human, rat, mouse and monkey.

Immunocytochemistry on cells expressing BACE. Acetone or methanol fixation preferred; 4% PFA 5′, RT followed by 0.1% triton X-100 1 hour, can also be used. 1:200-1:500 is recommended, optimization is necessary.

Immunoprecipitation:

Optimal working dilutions must be determined by end user.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Alzheimer′s disease (AD) is characterized by the progressive formation in the brain of insoluble amyloid plaques and vascular deposits consisting of the 4-kD amyloid b-peptide (Ab). Ab generation is initiated by proteolytic cleavage of the amyloid precursor protein (APP) at the N-terminal of Ab by b-secretase. The Ab peptide is then released by proteolytic cleavage at its C-terminus by g-secretase. Because both these proteases are prime candidates for therapeutic intervention, an intense search has been underway to identify these two enzymes.A human transmembrane aspartic-protease (Asp2), referred to as BACE, has been characterized and shown to have all the properties of b-secretase. Four groups in all have now confirmed that BACE (or Asp2) is a convincing candidate for b-secretase. r> r>BACE is an N-glycosylated integral membrane aspartyl protease with Mr=70 kDa. Mature BACE is produced from the immature form through a series of post-translational proteolytic cleavages and glycosylation. Sequence analysis has revealed that the immature form of BACE contains an N-terminal signal sequence (residues 1-21) followed by a large catalytic domain, a single transmembrane domain (residues 461-477), and a short cytoplasmic domain (residues 478-501). The signal sequence (1-21) is cleaved from the immature form by a signal peptidase located in the endoplasmic reticulum (ER), yielding the proBACE protein (Mr=75 kDa) which starts at residue 22. The proBACE protein is modified by cleavage of 24 N-terminal residues (aa 22-45), producing the mature BACE protein.

Immunogen

Epitope: C-terminus

Synthetic peptide corresponding to the C-terminus of human BACE.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Physical form

Protein A purified

Format: Purified

Purified immunoglobulin. Liquid. Buffer = 0.02M Sodium Phosphate, 0.25M NaCl with 0.1% sodium azide.

Specificity

Reacts with BACE (beta-site APP Cleaving Enzyme). Shows no reactivity to BACE2 by Western blot.

Storage and Stability

Maintain for 1 year at 2–8°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Target description

~ 60-75 kDa